Related Experiment Videos
Putting the bits and pieces of the RET proto-oncogene puzzle together
1Section of Endocrinology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Abstract:
The RET proto-oncogene has been implicated in the causation of papillary thyroid carcinoma, multiple endocrine neoplasia types 2A (MEN 2A) and 2B (MEN 2B), and Hirschsprung's disease. The mutations in these syndromes can be categorized into activating or inactivating mutations. Activating mutations of a cysteine-rich extracellular region cause enhanced dimerization of the RET tyrosine kinase receptor and autophosphorylation, and are causative for MEN 2A and familial medullary thyroid carcinoma (FMTC). An activating mutation of the tyrosine kinase domain causes increased autophosphorylation but does not affect the state of dimerization. A variety of inactivating mutations of the RET proto-oncogene, which result in defective protein formation, are causative for Hirschsprung's disease.
Insights
RET proto-oncogene mutations cause papillary thyroid carcinoma and Hirschsprung
Area of Science:
- Oncology
- Genetics
- Developmental Biology
Background:
- The RET proto-oncogene is crucial in cellular signaling and development.
- Dysregulation of RET is linked to various human diseases, including cancers and developmental disorders.
Purpose of the Study:
- To elucidate the distinct roles of RET proto-oncogene mutations in disease pathogenesis.
- To categorize RET mutations as activating or inactivating and link them to specific clinical outcomes.
Main Methods:
- Analysis of RET proto-oncogene mutations.
- Categorization of mutations based on functional impact (activating/inactivating).
- Correlation of mutation types with associated diseases.
Main Results:
- Activating RET mutations in the extracellular domain promote receptor dimerization and are linked to MEN 2A and FMTC.
- Activating mutations in the tyrosine kinase domain increase autophosphorylation without affecting dimerization.
- Inactivating RET mutations lead to defective protein formation, causing Hirschsprung's disease.
Conclusions:
- RET proto-oncogene mutations are key drivers in papillary thyroid carcinoma, MEN 2A/2B, and Hirschsprung's disease.
- The specific type and location of RET mutations dictate their functional consequences and associated pathologies.